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Objectives: Different jurisdictions organize their health technology assessment 
(HTA) capacity in different ways. In theory, a centralized approach offers the poten-
tial to pool the scarce resources devoted to HTA and national recommendations can 
be issued to encourage a uniform development of services across the whole country. 
On the other hand, a regional approach could help in tailoring recommendations to 
local needs. The objective of this study was to compare the assessment procedures 
in England (centralized approach) with Spain (regional approach). MethOds: We 
compared the assessments of the same cancer drugs in the two jurisdictions from 
2000 to 2015, extracting data on the availability of an HTA, the indication(s) studied, 
the comparator(s) considered, the cost-effectiveness assessments produced and the 
reimbursement recommendation (recommended with no restrictions, optimized 
or denied use). Results: The indications studied and the comparators considered 
were similar in the two jurisdictions. In England an HTA with a cost-effectiveness 
estimate was available for 105 drug/indication pairings: recommended (32%), opti-
mized(30%) and denied(38%). The Spanish HTA for pharmaceuticals is characterized 
by a high decentralization and lack of coordination. Decisions at national level 
were based on effectiveness and safety but no clear recommendations were made. 
Therefore we used data from two regional Governments (Andalucía and Cataluña) 
and a pharmacy scientific society (SEFH) where recommendations were stronger and 
considered cost-effectiveness. For the period of 2011-2014 a total of 43 indications 
were assessed in Cataluña: optimized (86%) exceptional use (14%). cOnclusiOns: 
Due to a relative lack of central coordination, the approach to HTA in Spain leads 
to a less standardized approach for technology assessments of cancer drugs than 
in England. In addition, cost-effectiveness evidence is less frequently generated. 
However, a lower proportion of drugs receive a negative recommendation, which 
may reflect both the lower level of cost-effectiveness scrutiny and a relatively higher 
willingness-to-pay.
patient-reported outcomes studies
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Objectives: To evaluate whether scores from paper (P) and electronic tablet (E) 
versions of seven PRO measures [SF-36v2 Health Survey (Standard), Bath Ankylosing 
Spondylitis Disease Activity Index, Health Assessment Questionnaire, Dermatology 
Quality of Life Instrument, Patient Global Assessment of Disease Activity, Subject 
Assessment of Pain, and, Fatigue Visual Analogue Scale are equivalent. MethOds: 
After establishing that patients interpreted P and E instruments in similar ways 
using cognitive interviews, a crossover study was conducted in 53 patients (34 
women) aged 18-83 years. A three-period design was used, with the first two peri-
ods being E and P in randomised order, the third period being P for all patients. This 
allowed both P-E and P-P reliabilities to be compared. Patients’ opinions on ease of 
use and acceptability of the electronic version were collected. Results: Intraclass 
Correlation Coefficients ranged from 0.75 to 0.97, all above the generally accepted 
threshold of .70. Correlations were in general similar for P-E (mode equivalence) 
and P-P (test-retest reliability for paper|) T-tests revealed no significant mean dif-
ference between P and E scores. Mean score differences between P and E measures 
were small and within an acceptable limit of equivalence. The majority of patients 
reported that the electronic tablet was acceptable (99%), and ‘very easy’ (81.8%) or 
‘quite easy’ (14.3%) to use. Few subjects (5%) reported problems using the tablet. The 
majority of patients (37; 74%) preferred the tablet version to paper, while 12 (24%) 
had no preference, and 1 (2%) preferred paper. cOnclusiOns: Results indicate 
that the PRO scores are equivalent when administered to patients with PsA via 
electronic and paper modes. The tablet versions were easy and acceptable to use, 
and preferred over paper versions. These results support the use of the electronic 
tablet versions of the PRO measures in PsA clinical trials.
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Objectives: Understanding the meaning of differences in HRQL scores is essential 
in communicating the value of treatment to stakeholders. This study translates 
differences in scores from a widely used HRQL measure, the SF-12v2, into differ-
ences in future medical expenditures across 5 major conditions. MethOds: Data 
came from the Medical Expenditures Panel Survey (MEPS; n= 20,624), collected in 
2006/2007. Conditions were identified by associated medical events, disability days 
or self-report. Medical expenditures (MEs) were calculated as the sum of payments 
for prescription medicines, hospital inpatient, emergency room, out-patient and 
office-based provider visits in the 6 months following administration of the SF-12v2. 
We modeled the effect of physical (PCS) and mental (MCS) component summary 
scores on MEs using logit-gamma two-part models that controlled for age, gender, 
marital status, comorbidities count and insurance status. Results: A 5-point lower 
PCS score was associated with a 22% increase in MEs among people with asthma and 
diabetes, 18% increase in migraine, 17% increase in depression and 14% increase in 
arthritis. 5-point lower MCS score was associated with a 9% increase in MEs among 
people with diabetes, 8% increase in migraine, 7% increase in arthritis and asthma 
and 4% in depression. The effect of PCS on MEs decreased with age in arthritis 
(P= 0.0210) and similarly for MCS in depression (P= 0.0365). A 5-point lower PCS was 
associated with a 25% increase in MEs in arthritis at age 45 but a 14% increase at age 
areas of the health care system. A critical appraisal was done covering the public HTA 
reports and the decisions for reimbursement of new therapies. Results: The HTA 
implementation started in 2013, but the first model of a scorecard HTA was abrogated 
in April 2014. From July 2014 the HTA responsibility moved at the National Drugs 
Agency and a new scorecard model was introduced. The Romanian HTA system is a 
quick-HTA based on a scorecard which sums up to 145 points, the criteria being: HAS 
(France) evaluation, NICE/SMC (UK) evaluation, IQWIG/G-BA (Germany) evaluation, the 
number of EU countries with reimbursement, the RWD study and the Budget Impact 
Analysis. There are two thresholds: over 80 points for unconditional reimbursement 
and 60-79 points for conditional reimbursements. By the end of 2014 were evaluated 
174 dossiers, including new INNs, new indications and new fixed dose combination. 
After the appeals done by MAHs, 23 new INNs were unconditionally included in the 
List and 51 INNs scored for conditional reimbursement, waiting for the cost-volume 
contracts to be signed in second semester of 2015. cOnclusiOns: The introduction 
of the scorecard HTA in Romania created the possibility to access for new drugs, in a 
transparent and objective manner, for the first time since 2008. The system does not 
require any cost-effectiveness model and has a predominant budget impact perspec-
tive for unconditional reimbursement, but created the circumstances to access on 
the List using commercial arrangements.
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impact of hta – an irish case study
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Health Information and Quality Authority (HIQA), Dublin, Ireland
Objectives: The Health Information and Quality Authority (HIQA) is a statutory, 
government-funded agency in Ireland which monitors the safety and quality of 
the healthcare and social care systems. HIQA has approximately 210 staff, with 7 
working in HTA. Since 2010 we have completed 7 full HTAs and 25 rapid HTAs in 
addition to 6 national HTA guidelines. This study sought to evaluate the impact 
of a national HTA. MethOds: In 2013 the Minister for Health requested that we 
examine the implications of establishing a national public access defibrillation 
(PAD) programme in Ireland to increase survival from out-of-hospital cardiac 
http://www.hiqa.ie/healthcare/health-technology-assessment/assessments/hta-
public-access-defibrillation. We sought to measure impact by analysing activity 
under four headings: internal processes; relevance of activity; value of activity; and 
communication of activity. Semi-structured questionnaires were circulated to key 
stakeholders for feedback. Results: Stakeholders indicated that they were happy 
with the management of the project and their opportunities to input into the HTA. 
The methodology used for the evaluation followed best practice, with the model 
reviewed by an external expert. The HTA was explicitly linked to a decision, and 
was found to strongly influence policy. The HTA took 308 person days to complete 
at an estimated cost of € 172,000. Public consultation resulted in over 100 comments 
from 20 individuals or organisations. The report was downloaded 502 times. There 
was greater activity associated with the public consultation version than with the 
final version. cOnclusiOns: The direct link to a policy decision meant that the 
HTA was likely to have high impact, this was supported by the scientific integrity of 
the report. The cost of producing the HTA compared favourably with, for example, 
NIHR funding for full HTAs in the UK. Where public consultation leads to changes in 
a report, it may be necessary to actively increase awareness of the final publication.
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developing a model
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Objectives: Health Technology Assessment (HTA) is the basis for drug reim-
bursement in many countries, however, it is not always clear how different factors 
are incorporated and weighted by HTA bodies. This research aims to develop a 
model that identifies the drivers of successful HTA submission in five European 
HTA agencies. MethOds: Single drug assessments conducted between January 
2011 and April 2015 were extracted from a database of HTA evaluations. The HTA 
outcome (recommendation for National Institute for Health and Care Excellence 
(NICE), Scottish Medicines Consortium (SMC) and Zorginstituut Nederland (ZIN); 
‘Amélioration du service médical rendu’ (ASMR) for Haute Autorité de Santé (HAS) 
and benefit rating for Gemeinsamer Bundesausschuss (G-BA)) and the clinical, 
economic and societal data underlying the assessment were collected. Factors 
influencing the outcome were determined by univariate and multivariate analy-
ses. Results: In total, 1019 HTAs were identified: 108 for G-BA, 464 for HAS, 68 for 
NICE, 218 for SMC and 69 for ZIN. Each model started with 63 explanatory variables, 
which were then refined by omitting variables that showed many missing values. A 
backward regression model was used to develop the models with the best fit. Models 
were chosen following several tests of goodness of fit: Akaike information criterion 
(AIC), likelihood-ratio, Wald-test and residual chi-square, resulting in country-spe-
cific models that predict factors with the best fit. cOnclusiOns: Univariate and 
multivariate backward regressions were used to develop models for understand-
ing the key drivers of HTA recommendations. In most countries, clinical factors 
appeared to be predictive factors for success. In countries performing economic 
evaluations, mainly economic factors appeared to be predictive factors. Societal 
factors were identified less frequently as predictive factors for recommendation. 
The difference in observations per country was a limitation for this research. Further 
research could expand the time horizon in order to increase the observations.
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free survival (PFS) and/or overall survival (OS) as reported outcomes and to create 
a RCT network accordingly. Fixed and random effects FP models of first/second 
order were applied on these data and tested for goodness of fit using deviance 
information criteria. Finally, the best fitting model was used to estimate the hazard 
function, median PFS, median OS and uncertainty of treatment effect. Results: 
Literature review found 8 RCTs and 5 RCTs which reported PFS and OS respec-
tively, for 7 different mRCC treatments (interferon-alfa (IFN), bevacizumab+IFN, 
temisrolimus+bevacizumab, sunitinib, pazopanib, cediranib, placebo). The best fit-
ting FP model was second order random effect model for both, PFS and OS NMA. 
Hazard functions varied significantly. Estimated median PFS was the longest with 
sunitinib (10.8 months; 95% credible interval (CI): 9.5-11.8), followed by pazopanib 
and temsirolimus+bevacizumab. Similarly, sunitinib was estimated with the 
longest median OS (28.8 months; 95% CI: 25.7-31.0) followed by pazopanib and 
bevacizumab+IFN. cOnclusiOns: Synthesis of NMA evidence for 1LmRCC treat-
ments identified sunitinib to be the treatment with favourable PFS and OS. When 
dealing with multiple sources, hazards proportionality assumption is violated, and 
proposed method should be the method of choice.
rm6
networK meta-analysis of biological response modifiers in 
rheumatoid arthritis including real world evidence at multiple 
time points
Jenkins D, Martina R, Bujkiewicz S, Dequen P, Abrams K
University of Leicester, Leicester, UK
Objectives: Network meta-analysis (NMA) is widely used to compare multiple 
interventions of interest when head-to-head comparisons of active treatments are 
not available. Most NMAs pool data from randomised controlled trials (RCTs) on a 
single clinical outcome. However, in the case of chronic diseases such as rheumatoid 
arthritis (RA), outcomes are often reported at different time points and long-term 
real-world data (RWD) is routinely collected as part of national registries. Evaluation 
of models for the inclusion of different time measures in NMA, especially from both 
a regulatory and reimbursement perspective, is thus warranted and is considered 
here. MethOds: RCTs and observational studies evaluating biological agents in RA 
were searched using standard filters and electronic databases. Networks of RCTs 
were supplemented with RWD to include outcomes extracted for as many time 
points as possible. Multivariate NMA models were extended to incorporate repeated 
measures, adjusting for correlation between time points and bias of RWD. Sensitivity 
and scenario analyses were performed to test different network sizes, correlation 
structures and bias adjustments. Results: Addition of RWD and studies reporting 
treatment effects at multiple time points significantly increased the evidence base 
for NMA in RA. The inclusion of RWD led to a reduction in the level of uncertainty 
around most of the effect estimates. Furthermore, the additional evidence from 
multiple times has potential of reducing uncertainty by ‘borrowing’ evidence and 
giving a fuller view of treatment effect over time, not just at a specific single time 
point. cOnclusiOns: Initial evaluation of these models in NMA indicates that 
extending an evidence base to include repeated measures and RWD maximises 
study network sizes and can significantly impact the level of uncertainty in treat-
ment effects. Further investigation of correlation and bias modelling is warranted, 
as too is the application of new NMA fractional polynomials model to RA.
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simulation optimisation of treatment sequences for rheumatoid 
arthritis
Tosh J, Stevenson M, Akehurst R, Strong M
University of Sheffield, Sheffield, UK
Objectives: Using simulated annealing (SA) to inform the economic evaluation 
of treatment sequences for rheumatoid arthritis (RA). MethOds: A discrete event 
simulation (DES) model was built to estimate lifetime costs and Quality Adjusted 
Life Years (QALYs) of alternative sequences for the treatment of patients with 
severe RA. Thirteen Disease Modifying Anti-Rheumatic Drugs (DMARDs) can be 
used sequentially, with a theoretical maximum size of the decision space of over 
10 billion unique sequences. This problem can be formulated as an optimisation 
problem – finding the treatment sequence that maximises net monetary benefit 
(NMB). However, it was not feasible to evaluate the NMB of every treatment sequence 
in the decision space. SA, a stochastic optimisation algorithm, was used to identify 
a sequence that was optimal, or near optimal. Given the evaluation of the NMB 
of some particular sequence by the DES model , the SA algorithm then selects a 
“nearby” sequence to evaluate. Better solutions are accepted, and worse solutions 
are sometimes accepted with a probability reducing as the algorithm progresses. 
This attempts to prevent the optimiser from getting stuck in a local optimum. 
Comprehensive tuning of the parameters of the SA algorithm was undertaken, 
and scenario analysis was performed. Results: At a willingness to pay of £30,000 
per QALY gained, the best performing sequence found was exclusively composed of 
conventional DMARDs. At £50,000 per QALY gained, the best performing sequence 
began with conventional DMARDs for the first four treatment lines, before beginning 
biologic DMARD treatment. The results were consistent when re-run, and when 
alternative specifications of the SA algorithm were used. cOnclusiOns: SA is a 
commonly used optimisation method, but it has rarely been applied in HTA. In this 
instance, SA performed well and may be an appropriate method for health resource 
allocation decision-making where there is a large decision space.
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comparison of timed automata with discrete event simulation for 
modeling personalized treatment decisions: the case of metastatic 
castration resistant prostate cancer
Degeling K, Koffijberg H, Schivo S, Langerak R, IJzerman MJ
University of Twente, Enschede, The Netherlands
Objectives: The aim of this study is to compare the usefulness of two prom-
ising alternative modeling techniques, Timed Automata (TA) originating from 
65. Similarly, a 5-point lower MCS score among those with depression was associated 
with a 10% increase in MEs at age 25 but 4% at age 55. cOnclusiOns: Differences in 
SF-12v2 scores, particularly PCS, had substantial impact on MEs, allowing enhanced 
interpretation of intervention-based improvements in SF-12v2 scores. In arthritis 
and depression, age significantly impacted the association between HRQL and MEs.
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condition specific utilities: impact on icer in a marKov model for 
multiple sclerosis
Versteegh M
Institute for Medical Technology Assessment, Rotterdam, The Netherlands
Objectives: Perceived and observed insensitivity of the EQ-5D instrument in cer-
tain clinical areas has led to the development of condition specific preference based 
instruments, also for Multiple Sclerosis (MS). It is uncertain how these instruments 
perform in economic evaluations. This study investigates the effect on the incre-
mental cost-effectiveness ratio (ICER) of using MS specific utility values rather than 
generic utility values. MethOds: A Markov model with a lifetime time horizon 
comparing symptom management with subcutaneous glatiramer acetate was based 
on a previously published study. The model has four EDSS health states and two 
relapse states, a one month cycle, accounts for age specific background mortality 
and discontinuation of therapy. Costs and effects were discounted with 3%. For 
this study, QALYs were calculated with utility values from the MSIS-PBM, a sensi-
tive condition specific utility instrument based on a Time Trade-off valuation of 
MSIS-29, and EQ-5D utility values. Values were both taken from the UK risk sharing 
scheme. Deterministic and Monte Carlo simulation based probabilistic sensitivity 
analyses were used to assess impact on ICER. Results: The mean ICER after 5000 
simulations was USD 291.545 using MS specific utilities, and 180.633 using EQ-5D 
based utilities. cOnclusiOns: This study used condition specific and generic util-
ity values in a hypothetical Markov model for relapsing remitting MS patients and 
showed that the incremental cost-effectiveness ratio was 60% higher when applying 
the condition specific utilities. Contrary to what might be expected, the condition 
specific utility instrument was not better at demonstrating treatment value than 
the generic EQ-5D.
pp4
the relationship between glucose-lowering medications, 
adherence, and outcomes in patients with type 2 diabetes
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Objectives: Adherent type 2 diabetes (T2DM) patients are more likely to have 
good glycaemic control than non-adherent patients, potentially resulting in bet-
ter outcomes. We investigated the association between the number of glucose-
lowering therapies, adherence and their impact on glycaemic control and quality 
of life (QoL). MethOds: Data were drawn from the 2013 Diabetes Disease Specific 
Programme, a large cross-sectional real-world survey of primary care physicians 
(PCP) and specialists and their patients consulting for diabetes. Physicians pro-
vided information regarding prescriptions, previous treatment and most recent 
HbA1cvalues. Patients completed the Morisky Measurement of Adherence Scale 
and the EQ-5D. Patients who had been on current treatment between 6 months and 
5 years and had values for all variables were included. A linear Structural Equation 
Model was developed to explore the relationships between the number of oral and 
injectable diabetes medications per day, adherence, glycaemic control and QoL 
while adjusting for confounding factors relating to duration and type of medica-
tion, existing complications, concomitant conditions, demographic and lifestyle 
factors. Results: 239 PCPs and 137 specialists across 5 EU countries provided data 
on 1209 T2DM patients. 58% patients were male, mean age 60.7 years (+/-10.3); num-
ber of oral medications 2.21 (+/-1.16); injectables 0.36 (+/-1.03); current HbA1c6.94% 
(+/-0.80). The model shows that a lower number of daily diabetes medications is 
positively associated with adherence [orals (β = -0.10, p< 0.001), injectables (β = -0.049, 
p< 0.001)]. Improved adherence is associated with a lower HbA1c (β = -0.10, p< 0.001), 
lower HbA1cis associated with improved QoL (β = -0.019, p< 0.001). cOnclusiOns: 
Controlling for important clinical and demographic factors, a lower number of daily 
glucose-lowering therapies is associated with greater adherence which, in turn, is 
associated with better glycaemic control and improved QoL. Further research is 
required to investigate if these associations vary depending on the specific medica-
tion taken or other patient-related parameters not considered here.
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networK meta-analysis of survival data using fractional 
polynomials – an example with first line metastatic renal cell 
cancer treatments
Mihajlovic J, Postma MJ
University of Groningen, Groningen, The Netherlands
Objectives: Summary survival data are available from published trials on first line 
metastatic renal cell cancer (1LmRCC) treatments. Survival on oncological treat-
ments in pharmacoeconomics is mainly estimated by fitting common parametric 
distributions over Kaplan Meier (KM) curves, assuming proportional hazards over 
time. Use of fractional polynomials (FP) allows for change of hazards over time and 
offers more freedom in distribution selection. This study aims to analyse exist-
ing survival data of 1LmRCC treatments through a network meta-analysis (NMA) 
and FP application. MethOds: A systematic literature review was performed to 
identify randomized clinical trials (RCT) of 1LmRCC treatments with progression 
